Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 483

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 483
---
. The Company has not experienced any losses on deposits since inception.

F-10

The Company’s accounts receivable is derived from customers located in the United States. The Company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses on customers’ accounts when deemed necessary. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay. Customer Concentration For the year ended December 31, 2023, two customers represented 51% and 48% of the Company’s revenue. For the year ended December 31, 2022, two customers represented 47% and 52% of the Company’s revenue, respectively. Additionally, two customers accounted for 44% and 56% of net accounts receivable as of December 31, 2023. One customer accounted for 100% of net accounts receivable as of December 31, 2022. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid marketable securities purchased with original maturities of three months or less at the time of purchase date to be cash equivalents. Restricted cash consists of a letter of credit secured by restricted cash in connection with one of the Company’s office leases described in Note 7, and is included in other assets on the consolidated balance sheets. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets (in thousands):

|                                                  |     | As of December 31, |   2023 |     |   |   2022 |
|:-------------------------------------------------|:----|:-------------------|-------:|:----|:--|-------:|
| Cash and cash equivalents                        |     | $                  | 62,888 |     | $ | 39,019 |
| Restricted cash, non-current                     |     |                    |     64 |     |   |     64 |
| Total cash, cash equivalents and restricted cash |     | $                  | 62,952 |     | $ | 39,083 |

Fair Value of Financial Instruments The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis